

March 5, 2009

CEO Billy Tauzin



CEO Jeff Kindler



President Obama



**Chairman
Karen Ignani**



**CEO Risa
Lavizzo-Mourey**




April 15, 2009

**White House Deputy Chief of Staff
Jim Messina**



Former Firm of White House Senior Advisor David Axelrod



April 20, 2009

President Obama



CEO Kevin Sharer



AMGEN®

April 20, 2009

**Chairman of U.S. Committee on Finance
Sen. Max Baucus**



CEO Kevin Sharer



AMGEN®

May 7, 2009

**Chairman of U.S. Committee on Finance
Sen. Max Baucus**



CEO David Brennan



AstraZeneca 

May 8, 2009

President Obama




CEO David Brennan



AstraZeneca 

May 11, 2009



(President Barack Obama meeting with healthcare stakeholders in the Roosevelt Room at White House May 11, 2009. Official White House Photo by Pete Souza)

June 2, 2009

CEO Billy Tauzin



P/RMA

CEO Jeff Kindler



Pfizer

Richard Smith



P/RMA

Miles White



Abbott
A Promise for Life

**Sarah Fenn - White House
Office of Health Reform**



**Lobbyist
James Hall**

P/RMA

CEO Kevin Sharer



AMGEN[®]

June 2, 2009

CEO Billy Tauzin



PhRMA

**Chairman of U.S. Committee on Finance
Sen. Max Baucus**



CEO Kevin Sharer



AMGEN®

CEO Jeff Kindler



Pfizer



Miles White



Abbott
A Promise for Life

June 20, 2009

COMMITTEE ON FINANCE
NEWS RELEASE



Max Baucus, Chairman
<http://finance.senate.gov>

For Immediate Release
June 20, 2009

Contact: Scott Mulhauser/Erin Shields
(202) 224-4515

**BAUCUS, PHARMACEUTICAL COMPANIES ANNOUNCE DEAL
TO REDUCE PRESCRIPTION DRUG COSTS FOR SENIORS**

*Finance Chair Secures \$80 Billion Commitment, Ensures Drug Discounts for Medicare Recipients
as Part of Effort to Reform Health Care, Reduce Costs, Ensure Quality*

Washington, DC – Senate Finance Committee Chairman Max Baucus (D - Mont.) announced he secured an \$80 billion commitment from the pharmaceutical industry to reduce Medicare prescription drug costs for seniors. The deal struck by Baucus and the nation's pharmaceutical companies with the participation of the White House includes a provision to narrow the gap in coverage, often called the "doughnut hole," with payments from the drug companies to cover up to 50 percent of the cost of brand-name medicine in Medicare's Part D prescription drug program.

July 7, 2009

**White House Chief of Staff
Rahm Emmanuel**



CEO David Brennan



Miles White



**White House Deputy
Chief of Staff Jim Messina**



CEO Jeff Kindler



CEO Billy Tauzin



**Lobbyist
James Hall**



CEO Kevin Sharer



CEO Richard Clark

